Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiovascular Imaging Reports
Erschienen in: Current Cardiovascular Imaging Reports 1/2012

01.02.2012 | Cardiac Molecular Imaging (F Jaffer, Section Editor)

FDG-PET-CT as a Biomarker for Aortic Valve Inflammation

verfasst von: Gagandeep S. Gurm, Ahmed Tawakol

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Calcific aortic stenosis (AS) is the most common heart valve disorder in the Western world. Invasive valve replacement (via surgery or percutaneously) is the sole therapy available at present in patients with symptomatic AS. In the past decade several animal and clinical studies have provided new insights into the pathogenesis of AS, suggesting it to be a consequence of an active inflammatory process similar to atherosclerosis. This knowledge has stimulated new hypotheses regarding a role for anti-inflammatory therapies in management of AS. Currently, anatomical imaging with echocardiography is the recommended modality for assessment and surveillance of AS. Biological imaging with newer molecular imaging techniques may be helpful in assessing valvular inflammation and may subsequently help in assessment of valvular effects of anti-inflammatory therapies. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is an emerging tool for quantifying inflammation within an atherosclerotic plaque. In this review, we discuss the role of anti-inflammatory therapy with statin drugs in management of AS with a focus on FDG-PET as a possible biomarker for aortic inflammation.
Literatur
1.
Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006;114:e84–e231.PubMedCrossRef
2.
Rajamannan NM, Bonow RO, Rahimtoola SH. Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med. 2007;4:254–62.PubMedCrossRef
3.
Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005;111:920–5.PubMedCrossRef
4.
Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiography study of a random population sample. J Am Coll Cardiol. 1993;21:1220–5.PubMedCrossRef
5.
Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142–7.PubMedCrossRef
6.
• Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29(3):630–4. Largest prospective study providing evidence that atherosclerosis and aortic valve disease have similar clinical risk factors.PubMedCrossRef
7.
Taylor Jr HA, Clark BL, Garrison RJ, et al. Relation of aortic valve sclerosis to risk of coronary heart disease in African-Americans. Am J Cardiol. 2005;95(3):401.PubMedCrossRef
8.
Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol. 2001;38(3):827.PubMedCrossRef
9.
Pohle K, Mäffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104(16):1927.PubMedCrossRef
10.
Katz R, Wong ND, Kronmal R, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation. 2006;113(17):2113.PubMedCrossRef
11.
Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90:844–53.PubMed
12.
O’Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoprotein B, (a), and E accumulate in the morphologically early lesion of degenerative’ valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996;16:523–32.PubMedCrossRef
13.
Olsson M, Thyberg J, Nilsson J. Presence of oxidised low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999;19:1218–22.PubMedCrossRef
14.
Mohler ER, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation. 2001;103:1522–8.PubMed
15.
Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181–4.PubMedCrossRef
16.
Peltier M, Trojette F, Sarano ME, et al. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol. 2003;91:97–9.PubMedCrossRef
17.
Otto CM. Aortic stenosis. Clinical evaluation and optimal timing of surgery. Cardiol Clin. 1998;16:353–73. vii.PubMedCrossRef
18.
Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997;95:2262–70.PubMed
19.
Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
20.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.CrossRef
21.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.PubMedCrossRef
22.
Inoue I, Goto S, Awata T, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000;67:863–76.PubMedCrossRef
23.
Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353:983–4.PubMedCrossRef
24.
Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926–31.PubMedCrossRef
25.
Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000;80:1095–100.PubMedCrossRef
26.
Luan Z, Chase A, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and −9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769–75.PubMedCrossRef
27.
Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825–31.PubMedCrossRef
28.
Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339(27):1972–8.PubMedCrossRef
29.
Albert MA, Danielson E, Rifai N, et al., for the PRINCE investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc. 2001;286:64–70.CrossRef
30.
Ridker PM, Cannon CP, Morrow D, et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8.PubMedCrossRef
31.
Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105:2660–5.PubMedCrossRef
32.
Rajamannan NM, Subramaniam M, Stock SR, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart. 2005;91:806–10.PubMedCrossRef
33.
Aronow WS, Ahn C, Kronzon I, et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693–5.PubMedCrossRef
34.
Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205–9.PubMedCrossRef
35.
Shavelle DM, Takasu J, Budoff MJ, et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002;359:1125–6.PubMedCrossRef
36.
Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004;110:1291–5.PubMedCrossRef
37.
Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723–30.PubMedCrossRef
38.
Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104:1927–32.PubMedCrossRef
39.
Antonini-Canterin F, Popescu BA, Huang G, et al. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J. 2005;6:119–24.PubMed
40.
Cowell SJ, Newby DE, Prescott RJ, et al., for the Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–97.PubMedCrossRef
41.
Moura LM, Ramos SF, Somorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554–61.PubMedCrossRef
42.
Rossebo AB, Pedersen TF, Boman, et al., for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.PubMedCrossRef
43.
•• Chan KL, Teo K, Dumesnil JG, et al., ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121(2):306–14. Trial studying the possible role of lipid-lowering therapy in regression of calcific aortic valve disease.PubMedCrossRef
44.
•• Rudd JHF, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography. Ready for prime time? J Am Coll Cardiol. 2010;55:2527–35. This review highlights the important evidence establishing the role of FDG-PET in atherosclerotic plaque imaging.PubMedCrossRef
45.
Garedew A, Henderson SO, Moncada S. Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. Cell Death Differ. 2010;17:1540–50.PubMedCrossRef
46.
Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003;112:645–57.PubMedCrossRef
47.
Kubota R, Kubota K, Yamada S, et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104–12.PubMed
48.
Rodriguez-Prados JC, Traves PG, Cuenca J, et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol. 2010;185:605–14.PubMedCrossRef
49.
Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–11.PubMedCrossRef
50.
Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818–24.PubMedCrossRef
51.
Tawakol A, Migrino RQ, Hoffmann U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol. 2005;12:294–301.PubMedCrossRef
52.
Graebe M, Pedersen SF, Borgwardt L, et al. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714–21.PubMedCrossRef
53.
Pedersen SF, Graebe M, Fisker Hag AM, et al. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010;31:423–9.PubMed
54.
Bural GG, Torigian DA, Chamroonrat W, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008;35:562–9.PubMedCrossRef
55.
Joly L, Djaballah W, Koehl G, et al. Aortic inflammation, as assessed by hybrid FDG-PET/CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification. Eur J Nucl Med Mol Imaging. 2009;36:979–85.PubMedCrossRef
56.
Rudd JHF, Myers KS, Bansilal S, et al. 18Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible Implications for Atherosclerosis Therapy Trials Journal of the American College of Cardiology. 2007;49.
57.
Kim TN, Kim S, Yang SJ, et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging. 2010;3:142–8.PubMedCrossRef
58.
•• Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010;3:388–97. This study establishes the possible role of FDG-PET plaque imaging in differentiating unstable atherosclerotic plaques from stable atherosclerotic plaques.PubMedCrossRef
59.
• Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611–20. This study establishes the possible role of FDG-PET plaque imaging in differentiating unstable atherosclerotic plaques from stable atherosclerotic plaques.PubMedCrossRef
60.
Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008;15:209–17.PubMedCrossRef
61.
Tahara N, Kai H, Ishibashi M, et al. Simvastatin Attenuates Plaque Inflammation: Evaluation by Fluorodeoxyglucose Positron Emission Tomography. J Am Coll Cardiol. 2006;j.jacc.2006.03.069.
62.
Ishii H, Nishio M, Takahashi H, et al. Comparison of Atorvastatin 5 and 20 mg/d for Reducing F-18 Fluorodeoxyglucose Uptake in Atherosclerotic Plaques on Positron Emission Tomography/Computed Tomography: A Randomized, Investigator-Blinded, Open-Label, 6-Month Study in Japanese Adults Scheduled for Percutaneous Coronary Intervention. Clin Ther. 2010;32:2337–47.PubMedCrossRef
63.
•• Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. The Lancet 2011. This study uses molecular imaging by FDG-PET to study therapeutic effects of dalcetrapib on atherosclerotic burden.
64.
Olsson M, Dalsgaard CJ, Haegerstrand A, et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol. 1994;23:1162–70.PubMedCrossRef
65.
Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111(24):3316–26.PubMedCrossRef
66.
Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;50:1992–8.PubMedCrossRef
67.
Stone PH. C-reactive protein to identify early risk for development of calcific aortic stenosis: right marker? Wrong time? J Am Coll Cardiol. 2007;50:1999–2001.PubMedCrossRef
68.
•• Marincheva-Savcheva G, Subramanian S, Qadir S, et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol. 2011;57:2507–15. This is the first study to show feasibility of using FDG-PET imaging to quantify inflammation within the diseased aortic valve.PubMedCrossRef
69.
Aikawa E, Nahrendorf M, Figueiredo JL, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116:2841–50.PubMedCrossRef
70.
71.
Gronholdt ML, Nordestgaard BG, Bentzon J, et al. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. J Vasc Surg. 2002;35:137–45.PubMed
72.
Wahlgren CM, Zheng W, Shaalan W, et al. Human carotid plaque calcification and vulnerability. Relationship between degree of plaque calcification, fibrous cap inflammatory gene expression and symptomatology. Cerebrovasc Dis. 2009;27:193–200.PubMedCrossRef
73.
Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009;2:107–15.PubMedCrossRef
74.
Aikawa E, Nahrendorf M, Sosnovik D, et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007;115:377–86.PubMedCrossRef
75.
Sui SJ, Ren MY, Xu FY, et al. A high association of aortic valve sclerosis detected by transthoracic echocardiography with coronary arteriosclerosis. Cardiology. 2007;108:322–30.PubMedCrossRef
76.
Mazzone A, Epistolato MC, Gianetti J, et al. Biologic features (Inflammation and Neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Clin Pathol. 2006;126:494–502.PubMedCrossRef
Metadaten
Titel
FDG-PET-CT as a Biomarker for Aortic Valve Inflammation
verfasst von
Gagandeep S. Gurm
Ahmed Tawakol
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Cardiovascular Imaging Reports / Ausgabe 1/2012
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-011-9117-1

Weitere Artikel der Ausgabe 1/2012

Current Cardiovascular Imaging Reports 1/2012 Zur Ausgabe

Cardiac Molecular Imaging (F Jaffer, Section Editor)

Molecular Imaging of Inflammation in Aortic Aneurysmal Disease

Cardiac Molecular Imaging (F Jaffer, Section Editor)

Molecular MRI of Inflammation in Atherosclerosis

Cardiac Molecular Imaging (F Jaffer, Section Editor)

Molecular Imaging of Macrophages in Atherosclerosis

Cardiac Molecular Imaging (F Jaffer, Section Editor)

Molecular MRI of Atherosclerosis Burden

Cardiac Molecular Imaging (F Jaffer, Section Editor)

Nanomedical Theranostics in Cardiovascular Disease

Cardiac Molecular Imaging (F Jaffer, Section Editor)

Imaging Cell Therapy for Myocardial Regeneration

Neu im Fachgebiet Kardiologie

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Sind Betablocker auch für ältere herzschwache Personen nützlich?

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko

15.04.2024 | ACC 2024 | Kongressbericht | Nachrichten

Selbstexpandierende TAVI-Klappen bei kleinem Aortenanulus im Vorteil

15.04.2024 | ACC 2024 | Kongressbericht | Nachrichten

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen